Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 899,300 shares, a drop of 35.3% from the September 30th total of 1,390,000 shares. Approximately 27.4% of the shares of the stock are short sold. Based on an average daily volume of 5,500,000 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 5,500,000 shares, the short-interest ratio is presently 0.2 days. Approximately 27.4% of the shares of the stock are short sold.

Aptevo Therapeutics Trading Down 5.2%

NASDAQ:APVO opened at $1.47 on Tuesday. Aptevo Therapeutics has a 1 year low of $1.32 and a 1 year high of $298.00. The firm has a 50 day moving average of $1.57 and a 200-day moving average of $3.80. The stock has a market capitalization of $4.83 million, a P/E ratio of 0.00 and a beta of 5.87.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($8.40) earnings per share for the quarter, topping the consensus estimate of ($83.20) by $74.80. As a group, analysts forecast that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on APVO shares. Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Aptevo Therapeutics to a “hold” rating in a research note on Thursday, September 18th. Wall Street Zen upgraded shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Roth Capital upgraded shares of Aptevo Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned about 1.32% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.